Joseph Doggett
Associate Professor of Medicine, Division of Infectious Diseases, School of Medicine · Oregon Health & Science University
Credentials: · · ·
History
Research
Drugs in development for toxoplasmosis: advances, challenges, and current status
Review · Drug Designing Open Access · 2017 · 253 citations
Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis
Proceedings of the National Academy of Sciences of the United States of America · 2012 · First of 15 authors · Corresponding · 151 citations
Journal of Medicinal Chemistry · 2016 · 82 citations
11 papers
- HA
9 papers
8 papers · 6 as a resident
- MS
3 papers
1 paper
- AN
1 paper
- AV
1 paper
- BP
1 paper · 1 as a resident
Grants
- 2019–2027
Novel Therapeutic Strategies for ELQ-422, a Preclinical Toxoplasmosis Drug Candidate
Department of Veterans Affairs · I01
Contact PI · Portland Va Medical Center
- 2021–2023
COVID19: Optimized Endosome-Targeting Compounds for SARS-CoV-2 and Emerging Coronaviruses
Department of Veterans Affairs · I01
Contact PI · Portland Va Medical Center
- 2016–2020
Development of Endochin-Like Quinolones for Babesiosis Therapy
National Institute of Allergy and Infectious Diseases · R01
PI · $688.6K · Yale University
- 2014–2018
Development of the Potent Anti-Malarial and Anti-Toxoplasma Drug, ELQ-316
Department of Veterans Affairs · IK2
Contact PI · Portland Va Medical Center